⚕️ The information below is for educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Consult your healthcare provider before starting any medication. Cost information is accurate as of April 2026 and subject to change.
GLP-1 medications represent one of the most significant breakthroughs in metabolic medicine in decades — but in India, they carry a price tag that puts them out of reach for most people without careful financial planning. Semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda) can cost ₹8,000–25,000 per month depending on the brand, dose, and source. For a condition that typically requires long-term or lifelong treatment, this adds up to ₹96,000–3,00,000 per year.
This guide covers the current state of insurance coverage for GLP-1 medications in India, legitimate cost-reduction strategies, generic availability, and how to have informed conversations with your insurer and your doctor.
| Product | Manufacturer | Indication | Monthly Cost (Approx) |
|---|---|---|---|
| Ozempic 0.5 mg/1 mg pen | Novo Nordisk | Type 2 diabetes | ₹9,000–12,000 |
| Ozempic 2 mg pen | Novo Nordisk | Type 2 diabetes | ₹14,000–18,000 |
| Rybelsus 3/7/14 mg (oral) | Novo Nordisk | Type 2 diabetes | ₹7,500–9,500 |
| Wegovy (semaglutide 2.4 mg) | Novo Nordisk | Obesity | Not officially launched in India as of April 2026 |
| Product | Manufacturer | Indication | Monthly Cost (Approx) |
|---|---|---|---|
| Victoza 1.2/1.8 mg | Novo Nordisk | Type 2 diabetes | ₹8,000–11,000 |
| Saxenda 3 mg | Novo Nordisk | Obesity | ₹18,000–25,000 |
The CDSCO approved the first Indian biosimilar semaglutide in 2024. Several manufacturers (Sun Pharma, Cipla, and others) have launched or are expected to launch biosimilar semaglutide products.
| Generic/Biosimilar | Manufacturer | Approx Monthly Cost |
|---|---|---|
| Semaglutide 0.5/1 mg (various brands) | Multiple Indian manufacturers | ₹3,500–6,000 |
Important: Ask your doctor whether a generic semaglutide is appropriate for your case. Biosimilars are approved for the same indications as the reference product and must meet CDSCO efficacy and safety standards.
As of 2026, GLP-1 medication coverage under Indian health insurance is inconsistent and policy-dependent. Here is what you need to know:
GLP-1 medications prescribed for Type 2 diabetes (Ozempic, Victoza, Rybelsus) are more likely to be covered because:
Practical steps:
This is where coverage falls sharply. Obesity is historically classified as a "lifestyle condition" by Indian insurers, and medications for weight loss are commonly excluded.
Exceptions that may allow coverage:
| Insurer | Diabetes Drug Coverage | Obesity Drug Coverage |
|---|---|---|
| Star Health | Partial (formulary-dependent) | Generally excluded |
| HDFC ERGO | Partial (select chronic disease plans) | Generally excluded |
| Niva Bupa | Partial | Excluded (as of 2025) |
| ICICI Lombard | Select corporate policies | Excluded |
| CGHS (Government) | Yes (select drugs) | Not covered |
| ESI (Employee State Insurance) | Yes (formulary) | Not covered |
Note: Insurance policies change frequently. Always verify directly with your insurer and request written confirmation of coverage for your specific medication before filling your first prescription.
Indian biosimilar semaglutide can cost 40–60% less than branded Ozempic. If your doctor agrees the biosimilar is appropriate, this alone can save ₹3,000–8,000 per month. Ask your endocrinologist or diabetologist specifically about CDSCO-approved Indian biosimilars.
Rybelsus (oral semaglutide 7 mg or 14 mg) costs ₹7,500–9,500/month — less than injectable Ozempic for many dose ranges. It requires taking the pill on an empty stomach with a small sip of water and waiting 30 minutes before eating. Discuss with your doctor whether oral semaglutide is appropriate for your condition.
Major hospitals with in-house pharmacies (AIIMS, Apollo, Fortis, Manipal) often negotiate better drug prices than independent pharmacies. If you are attending an outpatient clinic at a major hospital, ask the hospital pharmacy for pricing before buying at a retail chemist.
The Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) — the Jan Aushadhi scheme — operates over 10,000 generic medicine stores across India with significantly subsidised pricing. While GLP-1 medications are not currently widely available through this scheme, enquire at your nearest Jan Aushadhi Kendra, as the formulary expands regularly.
Novo Nordisk India (the primary GLP-1 manufacturer) and some distributors offer patient assistance programmes for qualifying patients. Criteria typically include demonstrated financial need and a prescription from a specialist. Contact Novo Nordisk India's customer support or ask your endocrinologist about available programmes.
Many large Indian employers (especially IT companies, BFSI sector, and MNCs) offer supplemental health benefits that include chronic disease management programmes. These may cover GLP-1 medications as part of a diabetes management benefit. Check with your HR department or benefits administrator.
Once you have achieved your target weight or blood glucose goals, your doctor may be able to reduce your dose — lowering costs while maintaining benefits. A maintenance dose of semaglutide 0.5 mg may be sufficient for some patients versus the full 2.4 mg weight-loss dose.
Ask your insurer for the complete list of covered medications (formulary). Look specifically for:
Most insurers require prior approval for expensive specialty medications. Your doctor must submit:
If your primary indication is obesity, document all metabolic comorbidities in your medical records before applying. A diagnosis of obesity with Type 2 diabetes is significantly more likely to be covered than obesity alone.
If your claim is denied, you have the right to appeal. File a written appeal with:
The Insurance Regulatory and Development Authority of India (IRDAI) has a consumer grievance portal. If you believe your insurer is incorrectly denying a covered benefit, file a complaint at igms.irda.gov.in.
Q: Is GLP-1 covered under Ayushman Bharat (PM-JAY)?
Currently, outpatient medications including GLP-1 agonists are not covered under PM-JAY, which primarily covers hospitalisation costs. Some state-level supplemental schemes may cover chronic disease medications — check with your state's health department.
Q: Can I claim GLP-1 costs on income tax?
Yes. Under Section 80D of the Income Tax Act, medical expenses for chronic conditions like diabetes can be claimed as a deduction. Medication costs prescribed by a registered medical practitioner are eligible. Consult a tax professional for your specific situation.
Q: My doctor prescribed GLP-1 off-label for PCOS weight loss. Will insurance cover it?
Off-label prescriptions face higher scrutiny from insurers. Coverage is unlikely without documentation of failed standard treatments and a strong letter of medical necessity from a specialist (endocrinologist or gynaecologist). The likelihood improves if you also have documented insulin resistance or prediabetes.
Q: Are there any free or subsidised GLP-1 programmes in government hospitals?
Semaglutide is increasingly available through government medical college hospitals (AIIMS, PGI, JIPMER) as part of clinical programmes or at subsidised rates. Ask your doctor whether enrolment in any such programme is possible.
Consult your healthcare provider before starting any medication. Prices quoted are approximate and based on April 2026 market data — verify current pricing with your pharmacy. This article is informational only and does not constitute financial, insurance, or legal advice.
